<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57044">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944033</url>
  </required_header>
  <id_info>
    <org_study_id>β2-agonist</org_study_id>
    <nct_id>NCT01944033</nct_id>
  </id_info>
  <brief_title>β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <authority>Tunisia: Ministry of Public Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness of β2-agonists in the treatment of exacerbations of COPD is already
      established. The purpose of this study is to compare the effectiveness of the β2-agonists
      alone in nebulization with the association β2-agonists  + Ipratropium bromide  in the
      treatment of an acute exacerbation of COPD consulting  the emergency departement based on
      the clinical and the aarterial blood gas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective study and randomized practiced in patients consulting the emergency
      departement for an acute exacerbation of COPD. The patients were divided in two groups:
      Group AB; received β2-agonists + Ipratropium bromide in nebulization and Group B received
      β2-agonists alone in nebulization)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>hospital admission and death rate</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>hospital admission rate and death rate</measure>
    <time_frame>24 hours after ED admission</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>dyspnea score</measure>
    <time_frame>120 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease Exacerbation</condition>
  <arm_group>
    <arm_group_label>Group AB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group AB; (n= 62) received β2-agonists + Ipratropium bromide in nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B (n= 44) received β2-agonists alone in nebulization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Ipratropium bromide</intervention_name>
    <arm_group_label>Group AB</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have known or suspected COPD based on pulmonary function test, arterial blood gas,
             clinical history, physical examination, and chest radiograph

          -  Age over 18 years old.

          -  COPD Exacerbation: FR&gt;25c/min PaCO2&gt;6Kpa PH&lt;7,35 SaO2&lt;90%

        Exclusion Criteria:

          -  GCS ≤ 12

          -  hypersensitivity to anticholinergic

          -  severe acidosis

          -  lack of patient cooperation

          -  serious heart arrhythmia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>semir nouira, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Monastir</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>nouira semir, MD</last_name>
    <phone>216073460144</phone>
    <email>semir.nouira@rns.tn</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Monastir</name>
      <address>
        <city>Monastir,</city>
        <state>Monastir</state>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fattouma Bourguiba University Hospital</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nouira Semir, MD</last_name>
      <phone>216 73532014</phone>
      <email>semir.nouira@rns.tn</email>
    </contact>
    <investigator>
      <last_name>Nouira Semir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Nouira</investigator_full_name>
    <investigator_title>Semir Nouira</investigator_title>
  </responsible_party>
  <keyword>β2-agonist</keyword>
  <keyword>Ipratropium Bromide</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease Exacerbation</keyword>
  <keyword>Emergency departement</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
